These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 11296615

  • 1. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
    Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel J.
    Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
    [Abstract] [Full Text] [Related]

  • 2. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
    Büntzel J, Küttner K, Fröhlich D, Glatzel M.
    Ann Oncol; 1998 May; 9(5):505-9. PubMed ID: 9653491
    [Abstract] [Full Text] [Related]

  • 3. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
    Büntzel J, Glatzel M, Kuttner K, Weinaug R, Fröhlich D.
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277
    [Abstract] [Full Text] [Related]

  • 4. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
    Vacha P, Marx M, Engel A, Richter E, Feyerabend T.
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
    [Abstract] [Full Text] [Related]

  • 5. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):739-47. PubMed ID: 11849797
    [Abstract] [Full Text] [Related]

  • 6. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, Richter E, Feyerabend T.
    Strahlenther Onkol; 2003 Jun 01; 179(6):385-9. PubMed ID: 12789464
    [Abstract] [Full Text] [Related]

  • 7. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [Abstract] [Full Text] [Related]

  • 8. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
    Büntzel J, Glatzel M, Schuth J, Weinaug R, Küttner K, Fröhlich D.
    Strahlenther Onkol; 1999 Nov 01; 175 Suppl 4():37-40. PubMed ID: 10584140
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB.
    Cancer; 2009 Oct 01; 115(19):4514-23. PubMed ID: 19634161
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL, Chao KS, Haughey B.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [Abstract] [Full Text] [Related]

  • 14. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A.
    Int J Radiat Oncol Biol Phys; 2006 Mar 01; 64(3):684-91. PubMed ID: 16243440
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R.
    J Clin Oncol; 2000 Oct 01; 18(19):3339-45. PubMed ID: 11013273
    [Abstract] [Full Text] [Related]

  • 17. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M, Levendag P.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S, Hoffmanns H.
    Strahlenther Onkol; 1999 Nov 01; 175 Suppl 4():30-3. PubMed ID: 10584138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.